Apple's next step in the health sector could be with Dexcom

Cramer often tells investors not to fall in love with their stock because getting close to their badets can blur their judgment. Last week, this was taken by surprise by Align Technology.

"Even if the numbers were not very good, stocks actually bounced back after being hit, normally when I see a stock go up because of bad news, it tells me that we have reached the lowest – there is no more selling, it is not the case this time, "warns Cramer. "If you still own Align Technology, you have to listen to it – I think you should actually unload some of your position because I do not like the direction this company might take."

The biggest problem of Cramer with the manufacturer Invisalign? Competition, especially from lower-cost competitors leveraging expired Align Technology patents.

"Look, Align Technology has brought a lot of money back to our viewers over the years, but Align with competitors is a totally different story from an Align without competitors," he explained.

And with the stock trading 35 times higher than next year's earnings estimates – a worrying figure if you do not think that Align can meet the forecasts, and that Cramer does so not – this dentist game seems more and more risky for the host "Mad Money".

"Here's the bottom line for a title we've always championed: Align Technology was one of the best-growing stocks in the market – it had a superior product and the stock deserved to skyrocket – but now Align counts many new competitors – it's a much less compelling story, "he said. "So, if you have this one, I invite you to take advantage of this recent strength and call the sacred register."